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Introduction
Esophageal cancer (EC) is the 8th most common 
cancer and the 6th leading cause of cancer-associated 
fatalities worldwide (Montgomery et al., 2014). More 
than 50% of patients have un-resectable or metastatic 
disease at the time of presentation with an age-adjusted 
incidence rate of about 4.5 per 100,000 (Thomas et al., 
2014). The 5-y relative survival for patients without nodal 
involvement is 37%, 18.4% with nodal disease and only 
3.1% for stage IV disease (Thomas et al., 2014; Tan et al., 
Abstract
Background: Precise staging of esophageal cancer (EC) is important for selection of optimal treatment option 
and prognostication. Aim of this study was to assess the role of 18FDG PET/CT in staging and response evaluation 
to neoadjuvant chemoradiation (nCR) in EC patients using standardized imaging protocol. Material and methods: 
This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan University Hospital 
Karachi, Pakistan from July 2017 till February 2018. We included 34 biopsy proven EC patients who had 18FDG 
PET/CT and CT of neck, chest and abdomen as part of initial staging. Eleven patients had post-nCR 18FDG PET/CT 
using standardized imaging protocol as per EANM guidelines. CT and PET/CT based staging was compared. Based 
on PERCIST criteria, response evaluation was assessed using change in highest SUVmax (%∆SUVmax) in baseline 
and follow-up scans (primary lesion, node or extra-nodal metastases). Results: Mean age of cohort was 57 ± 14 years 
(23 males and 11 females) having adenocarcinoma (AC) in 23 and squamous cell cancer (SCC) in 11 patients. Mean 
18FDG dose, uptake time and hepatic SUVmean for baseline scans were 169 ±54 MBq, 65 ±10 minute and 1.91 ± 0.49 
which were within ± 10%, ± 15% and ± 20% for follow-up scans in 11 patients respectively. Mean size (craniocaudal 
dimension in mm) and SUVmax of primary tumor was 56 ±27 mm and 13.4 ± 4.7. Based on 18FDG PET/CT findings, 
patients were categorized into N0 (10/34), N1 (09/34), N2 (11/34) and N3 (04/34) while 11/32 had stage IV disease. 
No significant difference was seen in AC and SCC groups. CT found stage IV disease in 3/34 (09%) while PET/CT 
found in 11/34 (32%; p value: 0.019) cases. PET/CT showed concordance with CT in 41% while discordance (all 
with upstaging) seen in 59%. On follow-up PET/CT, complete metabolic response was seen in 5/11 (45%) and partial 
metabolic response was noted in 6/11 (55% - p value non-significant) patients. Median %∆SUVmax over primary 
lesions was 49.84% (-32.69 -100%) while over nodal sites it was 41.18% (-82.60 -100%). Conclusion: We conclude 
that 18FDG PET/CT was found a sensitive tool in initial staging of EC. Compared with CT, it had higher diagnostic 
accuracy for distant nodal and extra-nodal metastasis. %∆SUVmax between baseline and post-nCR studies acquired 
with standardized protocol had changed management in more than half of our patients. For response evaluation in EC 
more studies with standardized 18FDG PET/CT imaging protocols are warranted.
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2014). Therefore, disease stage has profound prognostic 
implications as for patients with localized disease are 
offered surgery or definitive chemoradiation but those 
with locally aggressive disease have option of neoadjuvant 
chemoradiation (nCR) with or without surgery (Talsma 
et al., 2012). 
Endoscopic ultrasound (EUS) has good diagnostic 
accuracy to detect extent of mucosal involvement and 
peri-lesional nodal metastasis but could have limited 
access in locally advanced disease. Computerized 
tomography (CT) has good diagnostic accuracy for tumor 
Editorial Process: Submission:04/06/2018  Acceptance:06/06/2019
1Section of NM and PET/CT imaging, Department of Radiology, 3Department of Radiation Oncology, Aga Khan University 
Hospital (A KUH), 2Dow Medical College, Dow University of Health Sciences (DUHS),  Karachi, Pakistan. *For Correspondence: 
maseeh.uzzaman@aku.edu
Nosheen Fatima et al
Asian Pacific Journal of Cancer Prevention, Vol 202004
staging (T-staging) but has lower sensitivity for nodal or 
distant metastasis (Chatterton et al., 2009). PET/CT using 
18-Flourodeoxyglucose (18FDG) is more accurate tool 
for staging, prognostication and can change management 
in more than one third of patients (Duong et al., 2006). 
However, it has limited value in the assessment of the 
primary tumor and detection of peri-tumoral nodal disease 
(Thomas et al., 2014). Reported sensitivity and specificity 
of 18FDG PET/CT using maximum standardized uptake 
value (SUVmax) for response evaluation of nCR are 
67% and 68% respectively (Leijenaar et al., 2015). 
However, published studies lack standardization in 
imaging protocols which could result in unknown biases 
and reproducibility of SUVs and SUV-based response 
assessment (Boellaard, 2011).
Aim of this study was to assess the role of 18FDG PET/
CT in staging and response evaluation to neoadjuvant 
chemoradiation in EC patients using standardized imaging 
protocol.
Materials and Methods
This prospective study was conducted at PET/CT 
Section of Department of Radiology, Aga Khan University 
Hospital Karachi, Pakistan from July 2017 till February 
2018. We included patients with EC who were referred 
for 18FDG PET/CT studies at baseline and those who 
had follow-up after completion of nCR during study 
period. All patients had endoscopic biopsies and contrast 
enhanced CT of neck, chest and abdomen as part of initial 
staging work-up. We strictly followed a standardized 
protocol for 18FDG PET/CT as per European Association 
of Nuclear Medicine (EANM) guidelines for both studies 
(Boellaard et al., 2015). Staging of EC based on CT and 
baseline PET/CT scans were compared. In patients who 
had follow-up PET/CT studies, response evaluation was 
assessed using change in highest SUVmax (%∆SUVmax) 
in baseline and follow-up scans (primary lesion, node or 
extra-nodal metastases). 
Inclusion Criteria
Patients with biopsy proven EC who were referred 
for 18FDG PET/CT imaging for staging and also had CT 
examination of neck, chest and abdomen as part of their 
initial staging work at our institute were included. Those 
without complete CT studies were not included. 
CT Imaging
All patients had baseline contrast enhanced CT 
examinations done within 2 weeks prior to baseline 
18FDG PET/CT studies. CT scans were reported by 
our radiologists for primary tumor size and extent, 
peri-lesional nodal / visceral involvement and distant 
nodal and non-nodal metastasis. Staging was done using 
manual of American Joint Committee on Cancer 7th 
edition (AJCC 7th Ed) (Edge and Compton, 2010).
18FDG PET/CT Imaging
18FDG PET/CT was performed as per institutional 
protocol adopted from EANM guidelines (Boellaard et 
al., 2015). All patients had 4-6 hour fasting (only plain 
water was allowed) and a fasting blood sugar less than 
200 mg% before receiving an intravenous 18FDG dose of 
3 MBq/Kg in the uptake room. During uptake period (55 
-75 minute) patients were requested to lie comfortably 
and allowed to take about 500-1,000 ml of plain water. 
Bladder was emptied prior to call the patient for PET/CT 
imaging suite equipped with Celesteion, Toshiba, Japan. 
A low dose CT examination (mid brain to mid-thigh) from 
head to toe followed by acquisition of PET imaging using 
3 minute/bed position from toe to head in all patients. 
Follow up scans were performed with same protocols, 
keeping 18FDG dose, uptake time and hepatic SUVmean 
of baseline and follow-up studies within ± 10%, ± 15% 
and 20% minutes respectively as per PET response criteria 
in solid tumor (PERCIST) (Wahl et al., 2009). SUVmax 
of primary lesions and nodal disease were measured in 
both studies and also % change in highest SUVmax of 
baseline and follow-up studies for response evaluation 
as recommended by PERCIST criteria.
Statistical Analysis
Continuous variables were described by mean ± standard 
deviation (SD). Comparisons between patient groups of 
two histological types of CA esophagus were performed 
using Student’s t test for continuous variables and the χ2 
test for categorical variables. Statistical significance was 
defined as P<0.05. Commercially available packages 
Microsoft excel 2010, Medcalc® and statistical package 
for social sciences (SPSS 19®) were used. 
Results
Study included 34 patients with biopsy proven EC, 
having a mean age of 57 ± 14 years (23 males and 11 
females) and a mean BMI (kg/m2) of 23.92 ± 4.81. Twenty 
three patients had adenocarcinoma (AC) while 11 had 
squamous cell cancer (SCC). All patients had baseline 
18FDG PET/CT prior to nCR and only 11 had follow-up 
studies during study period for response evaluation. 
Mean 18FDG dose, uptake time and hepatic SUVmean 
for baseline scans were 169 ±54 MBq, 65 ±10 minute and 
1.91 ± 0.49 (Table 1). These values were within ± 10%, 
± 15% and ± 20% for follow-up scans in 11 patients 
respectively. Mean size (craniocaudal dimension in mm) 
and SUVmax of primary tumor was 56 ±27 mm and 13.4 
± 4.7. Based on 18FDG PET/CT findings, patients were 
categorized into N0 (10/34), N1 (09/34), N2 (11/34) and 
N3 (04/34) while 11/32 had stage IV disease (Table 1). 
Histopathology revealed AC in 23/34 and SCC in 
11/34 patients. No significant difference was seen in both 
groups for mean age, gender, BMI, mean tumor size or 
mean tumor SUVmax. Similarly no significant difference 
was noted for nodal involvement (N0-N3) or stage IV 
disease between AC and SCC groups (Table 2). 
CT found stage IV disease in 3/34 (09%) while PET/
CT found in 11/34 (32%; p value: 0.019) cases (Figure 1). 
A concordance in staging between CT and PET/CT was 
seen in 14/34 (41%) patients. However, in 20/34 (59%) 
patients PET/CT upstaged the disease due to new lesions 
seen in nodes (12/20) and distant metastasis (08/20). 
18FDG PET/CT was not found to downstage the disease 
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in any patient (Table3).
Eleven patients had a follow-up 18FDG PET/CT for 
response evaluation to nCR. Using PERCIST criteria, 
complete metabolic response (disappearance of all 
abnormal 18FDG uptake; CMR) was seen in 5/11 (45%) 
(Figure 2) while partial metabolic response (>30% decline 
in highest SUVmax; PMR) was noted in 6/11 (55% - p 
value non-significant) patients (Figure 3,4). Median 
%∆SUVmax over primary lesions was 49.84% (-32.69 
-100%) while over nodal sites it was 41.18% (-82.60 
-100%) (Figure 5). 
Discussion
Esophageal cancer (EC) is one of the most aggressive 
tumors with higher recurrence rate even after radical 
surgery. Therefore precise pretreatment staging is 
important to determine appropriate stage-specific 
treatment options. CT based staging has limited 
sensitivity (30-60%) and specificity (60-80%) for nodal 
metastasis as it relies on anatomic criteria (Napier et 
al., 2014) and also for distant metastasis due to delayed 
appearance of appreciable morphological changes over 
those sites. However, in recent years 18FDG PET/CT has 
shown a better diagnostic accuracy for nodal and distant 
Variables N=34
Age in years     57 ± 14
Mean ± SD  (range)  (26-85 yrs)
Gender  (Male: Female) 23: 11 (68: 32%)
BMI (Kg/m2) Mean ± SD 23.92 ± 4.81
FDG Dose (MBq) Mean ± SD 169 ± 54
FBS (mg/dl)   Mean ± SD 101 ± 26
Duration (minutes)  Mean ± SD 65 ± 11
CTDI  (Mean ± SD) 5.17 ± 0.92
DLP  (Mean ± SD) 570.62 ± 103.59
Mean Liver uptake  (Mean ± SD) 1.91 ± 0.49
SD of mean liver uptake  (Mean ± SD) 0.26 ± 0.11
Adenocarcinoma: SCC 23: 11 (68:32%)
SUVmax of tumor ( Mean ± SD) 13.4 ± 4.7
Size of tumor in mm ( Mean ± SD ) 56 ± 27
Nodal involvement (N0:N1:N2:N3) 10: 09:11:04
(29:27:32:12%)
Stage IV 11 (32%)
Table 1. Study Demographics
BMI, Body Mass Index; SD, Standard Deviation; FDG, Flurodeoxy 
Glucose; FBS, Fasting Blood Sugar; CTDI, CT dose index; DLP, Dose 
Length Product; SUV, Standardized Uptake Value; SCC, Squamous 
Cell Carcinoma
Figure 1. 70 Years Old Male, Known Case of Esophageal Cancer, Baseline 18FDG PET/CT for Staging Showing 
Hypermetabolic Circumferential Soft Tissue Mass Involving Esophagus from Carina to GE Junction (2nd and 5th 
rows), a hypermetabolic gastrohepatic lymph node (1st row), 18FDG avid left pulmonary nodules (3rd row) and 
hypermetabolic left adrenal (2nd row) and solitary bony metastasis in right iliac blade (4th and 5th rows; Stage IV).
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metastasis compared to contrast enhanced CT (Lu et 
al., 2016). In our study, we had a higher prevalence of 
AC than SCC (primary lesion in distal esophagus and at 
gastroesophageal junction) which is significantly higher 
than South America but in concordance with Western 
Europe and North America which is possibly due to the 
increase of obesity and gastroesophageal reflux disorder 
(GERD) incidence in these regions (Thomas et al., 2014; 
Tustumi et al., 2016). In our study, GERD could be the 
possible reason for higher incidence of AC as BMI of 
our total cohort was not high. In this study no significant 
difference was seen in BMIs of patients with SCC and 
AC which is in concordance with published study (Lu 
et al., 2016) 
Table 2. Demographic Comparison of Adenocarcinoma and Squamous Cell Carcinoma of Esophagus on Baseline 
PET/CT Scan
Adenocarcinoma N=23 SCC N=11 χ2/ or t-test values p-values
Age in years 56 ± 12 59 ± 17 0.595 0.556
Mean ± SD (range) (33-77) (26-85)
Gender  (Male: Female) 17: 06 (74:26%) 06:05 (55:45%) 1.195 0.274
BMI (Kg/m2) Mean ± SD 24.09 ± 5.05 23.56 ± 4.49 -0.296 0.769
SUVmax of tumor (Mean ± SD) 12.8 ± 4.4 15.3 ± 5.0 1.484 0.148
Size of tumor in mm (Mean ± SD) 56 ± 29 56 ± 23 0 1
Nodal involvement
     N0 07 (30%) 03 (27%) 0.032 0.859
     N1 05 (22%) 04 (36%) 0.726 0.394
     N2 08 (35%) 03 (27%) 0.211 0.646
     N3 03 (13%) 01 (10%) 0.061 0.804
Stage IV 09 (39%) 02 (18%) 1.459 0.227
Upstaging 14 (60%) 06 (55%) 0.074 0.785
Nodal 08 (57%) 04 (67%) 0.102 0.749
Distant 06 (43%) 02 (33%) 0.102 0.749
SD, Standard Deviation; BMI, Body Mass Index; SUV, Standardized Uptake Value; SCC, Squamous Cell Carcinoma
Figure 2. 34 Years Old Female, Known Case Distal Esophageal Cancer, 18FDG PET/CT MIP Images at Baseline 
(Left) and Follow-up (Right) Showing Complete Metabolic Response (CMR) Over Primary Site after Neoadjuvant 
Chemoradiation. Brown adipose tissue uptake seen in bilateral supraclavicular baeline MIP scan (Responder).





     Nodes 12 (60%)
     Distant 08 (40%)
(Liver: Bone: Lungs: Adrenals) 03:01:03:01 
(38%: 12%: 38%: 12%)
DOWNSTAGING 0%
Table 3. Change in Staging by Comparing Baseline 
18FDG PET/CT with CT
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In our study nodal involvement was seen in about 
two third cases at initial staging (no difference between 
SCC and AC groups) which could be explained by dual 
lymphatic drainage of esophagus (one plexus arising 
within mucosal and other within muscular layers) (Napier 
et al., 2014). In our study incidence of nodal metastasis 
was similar in AC and SCC which is in contradiction to 
published fact that submucosal AC has lower prevalence 
of nodal and skip metastasis than SCC (Cho et al., 
2014). This could be explained by a significantly higher 
sensitivity (up to 90%) of 18FDG PET/CT for distant 
nodal metastasis than locoregional nodes (Napier et al., 
2014). A meta-analysis of 12 previous studies revealed 
that sensitivity of 18FDG PET/CT for regional nodal 
metastasis was significantly lower than that of CT (51% vs 
63%–87%), but the specificity was higher than CT (84% 
vs. 14%–43%) (Cho et al., 2014). The lower sensitivity 
of 18FDG PET/CT might result from the difficulty in 
differentiating the primary tumor from peri-tumoral lymph 
nodes because of intense 18FDG uptake by the tumor, as 
well as from false-positive findings due to inflammatory 
enlarged nodes (Hing et al., 2014). The overall incidence 
of distant metastasis in this study was 32% (liver > lung 
> bone > adrenal) which is in concordance with published 
data (Napier et al., 2014). In this study incidence of distant 
metastasis was higher in AC (39%) than SCC (18%) which 
is also reported in other demographic studies (Tavirani 
et al., 2017). However, it was statistically not significant 
which is likely due to small sample size. However, this 
might raise the possible higher hematogenous spread in 
AC than SCC which needs to be explored. 
In this study concordance between CT and 18FDG 
PET/CT for initial staging was found in 41% which is in 
concordance with a published study (45% concordance) 
having almost a similar patient population (40 patients) 
(Tan et al., 2016). However, concordance in our study 
is well below another study published study (60% 
concordance) having a higher patient population (139 
Figure 3. 75 Years Old Male with Known Case of Mid Esophageal Cancer, 18FDG PET/CT MIP Images at Baseline 
(Left) and Follow-up (Left) Showing Partial Metabolic Response (PMR) Over Primary and Loco- Regional Nodes and 
Resolution of 18FDG Non-Avid Bilateral Pulmonary Nodules (Non-Responder).
Figure 4. Metabolic response on Follow-up 18FDG PET/
CT in Esophageal Cancer Patients who Underwent 
Neoadjuvant Chemoradiation (nCR).
Figure 5. Median % Change in SUVmax Over Primary 
and Nodal Sites of Esophageal Cancer Patients between 
Baseline and Post-nCR 18FDG PET/CT Studies
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patients) (Thomas et al., 2014). This could be explained by 
strict CT reporting criteria in our study particularly about 
size of nodes (abnormal nodes = >10 mm in short axis). 
Similarly discordance between CT and 18FDG PET/CT for 
initial staging was found in 59% and all led to upstaging 
(no down staging) which is not in concordance with 
published results (Thomas et al., 2014; Tan et al., 2016). 
This could be explained by established higher diagnostic 
accuracy of 18FDG PET/CT than CT for distant metastasis 
(Napier et al., 2014) and stringent CT reporting criteria 
adopted by our radiologists. 
In EC accurate response evaluation to nCR is 
imperative to omit surgery in complete responders or 
prevent unjustified nCR in non-responders. 18FDG PET/
CT using SUVmax for evaluation of response to nCR has a 
sensitivity of 67% and specificity of 68% (Beukinga et al., 
2017). We found clinical CMR in 45% and clinical PMR in 
55% to nCR in 11 patients who had a post-treatment study. 
Our CMR rate is in concordance with recently published 
studies having rates of 61% (Elimova et al., 2015) and 
46% (Gunther et al., 2015) respectively. 
Our study has some limitations. First it has a small 
sample size which increases uncertainty and relatively 
less precision. However, like other small sample sized 
published studies, this could always be used for meta-
analysis in future. Second, we had used only SUVmax 
and no other parameters like total lesion glycolysis or 
texture for response evaluation. Third, we did not validate 
our results with pathology; instead we used % change in 
18FDG uptake as validation criterion which is a major 
limitation.  However, we had used a standardized imaging 
protocol for 18FDG PET/CT for baseline and follow-up 
which significantly improves precision of %∆SUVmax 
by minimizing the impact of various confounding factors 
associated with non-standardized protocols. 
We conclude that 18FDG PET/CT was found a 
sensitive tool in initial staging of EC. Compared with CT, 
it had higher diagnostic accuracy for distant nodal and 
extra-nodal metastasis. %∆SUVmax between baseline and 
post-nCR studies acquired with standardized protocol had 
changed management in more than half of our patients. For 
response evaluation in EC more studies with standardized 
18FDG PET/CT imaging protocols are warranted.
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